Skip Navigation



JAC Advance Access published online on December 12, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg055
© 2002 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
51/1/157    most recent
dkg055v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jones, R. N.
Right arrow Articles by Rhomberg, P. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. N.
Right arrow Articles by Rhomberg, P. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 The British Society for Antimicrobial Chemotherapy

Report

Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor

Ronald N. Jones 1 Paul R. Rhomberg 2*

1 The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317; Tufts University School of Medicine, Boston, MA, USA
2 The JONES Group/JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317

* Corresponding author. E-mail: paul-rhomberg{at}jmilabs.com.

Received 17 September 2002 ; revised 8 October 2002 ; accepted 22 October 2002

Abstract

The antibacterial activity of NVP-PDF386 (VRC4887), a novel peptide deformylase (PDF) inhibitor, was tested against over 1000 recent clinical isolates collected during 2001 and 2002. The MIC50/90 (mg/L) results for NVP-PDF386 (VRC4887) were: Staphylococcus aureus (SA) 0.5/1, coagulase-negative staphylococci (CoNS) 0.5/1, Streptococcus pneumoniae 0.25/0.5, other streptococci 0.25/0.5, enterococci 1/2, Moraxella catarrhalis 0.25/0.25, Haemophilus influenzae 8/32 and Enterobacteriaceae or non-fermentative Gram-negative bacilli >32/>32 mg/L. No differences in NVP-PDF386/(VRC4887) MIC distributions were observed between methicillin-resistant (MR) S. aureus and methicillin-susceptible (MS) S. aureus, MR-CoNS and MS-CoNS, penicillin-susceptible and non-susceptible streptococci, and macrolide-susceptible and -resistant strains. The potency of NVP-PDF386 (VRC4887) compared favourably with those of control compounds, including glycopeptides, oxazolidinones, a streptogramin combination and other agents with activity focused against Gram-positive cocci.

Keywords: antimicrobial activity, peptide deformylase inhibitor, NVP-PDF386
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
A. A. Watters, R. N. Jones, J. A. Leeds, G. Denys, H. S. Sader, and T. R. Fritsche
Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004)
J. Antimicrob. Chemother., May 1, 2006; 57(5): 914 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
T. R. Fritsche, H. S. Sader, R. Cleeland, and R. N. Jones
Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance
Antimicrob. Agents Chemother., April 1, 2005; 49(4): 1468 - 1476.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Ramanathan-Girish, J. McColm, J. M. Clements, P. Taupin, S. Barrowcliffe, J. Hevizi, S. Safrin, C. Moore, G. Patou, H. Moser, et al.
Pharmacokinetics in Animals and Humans of a First-in-Class Peptide Deformylase Inhibitor
Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4835 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. M. Ednie, G. Pankuch, and P. C. Appelbaum
Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4027 - 4032.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Credito, G. Lin, L. M. Ednie, and P. C. Appelbaum
Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4033 - 4036.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Lofland, S. Difuntorum, A. Waller, J. M. Clements, M. K. Weaver, J. A. Karlowsky, and K. Johnson
In vitro antibacterial activity of the peptide deformylase inhibitor BB-83698
J. Antimicrob. Chemother., April 1, 2004; 53(4): 664 - 668.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Gross, J. Clements, R. P. Beckett, W. Thomas, S. Taylor, D. Lofland, S. Ramanathan-Girish, M. Garcia, S. Difuntorum, U. Hoch, et al.
Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor
J. Antimicrob. Chemother., March 1, 2004; 53(3): 487 - 493.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.